Durlobactam

Durlobactam
Clinical data
Other names	ETX2514
Routes of; administration	Intravenous
Drug class	Antibacterial, beta-lactamase inhibitor
ATC code	None;
Legal status
Legal status	US: ℞-only co-packaged with sulbactam;
Identifiers
	IUPAC name [(2S,5R)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-en-6-yl] hydrogen sulfate;
CAS Number	1467829-71-5;
PubChem CID	89851852;
DrugBank	DB16704; DBSALT003190;
ChemSpider	57617784; 71060725;
UNII	PSA33KO9WA; F78MDZ9CW9;
KEGG	D11591; D11592;
ChEMBL	ChEMBL4298137; ChEMBL4297378;
Chemical and physical data
Formula	C8H11N3O6S
Molar mass	277.25 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C[C@@H]2C[N@]([C@@H]1C(N)=O)C(=O)N2OS(O)(=O)=O;
	InChI InChI=1S/C8H11N3O6S/c1-4-2-5-3-10(6(4)7(9)12)8(13)11(5)17-18(14,15)16/h2,5-6H,3H2,1H3,(H2,9,12)(H,14,15,16)/t5-,6+/m1/s1; Key:BISPBXFUKNXOQY-RITPCOANSA-N;

Durlobactam is a beta-lactamase inhibitor used in combination with sulbactam to treat susceptible strains of bacteria in the genus Acinetobacter^[1] It is an analog of avibactam.

The combination therapy sulbactam/durlobactam was approved for medical use in the United States in May 2023.^[1]

References

^ ^a ^b "FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria". U.S. Food and Drug Administration (Press release). 24 May 2023. Retrieved 24 May 2023. This article incorporates text from this source, which is in the public domain.